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Maxillary bone loss is commonly found in humans, due to bone ageing, tooth loss, 
periodontal disease and, more severely, to trauma, radiotherapy and tumor 
resection. Maxillofacial reconstructive surgery is a still unmet clinical demand. 
Available therapies include grafting of autologous or heterologous bone tissue 
and/or the implantation of metallic plates, but these treatments are still unable to 
resume form and function. The emergence of 3D-printing technology applied to 
metal alloys now allows the manufacturing of customized, patient-tailored 
prosthetic implants. However, poor bone quality at the implant site due to ageing 
or disease still hamper proper osseointegration. By combining Electron Beam 
Melting (EBM) metal sintering and tissue engineering, we are developing hybrid 
maxillofacial implants, where a metal framework of Ti6Al4V alloy confers both an 
appropriate shape and mechanical stability, while stem cells and osteogenic 
molecules stimulate bone growth into the metal framework, thus promoting 
osseointegration. We hereby present the in vitro work driving to the development 
of our hybrid maxillofacial prostheses, as well as the setting up of an in vivo model 
of complete maxilla full resection, created in order to test the prostheses in a 
preclinical study. 
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